INTRO-01 | Introduction to home parenteral nutrition | 0 |
INTRO-02 | Methods used to develop the guideline | 0 |
R1 | HPN when oral or enteral intake is insufficient | 0 |
R10 | Place exit site where patient can see and reach it | 0 |
R11 | Use tunneled or implanted CVAD for long-term HPN | 0 |
R12 | Prefer upper vena cava access via jugular or subclavian | 0 |
R13 | Prefer right-sided CVAD access to reduce thrombosis | 0 |
R14 | Position CVAD tip at the cavoatrial junction | 0 |
R15 | PICC acceptable when HPN is expected under six months | 0 |
R16 | Use an infusion pump for HPN | 0 |
R17 | Limit flow regulators to exceptional temporary use | 0 |
R18 | Portable pump can improve quality of life | 0 |
R19 | Cover CVAD exit site with sterile dressing | 0 |
R2 | HPN as primary therapy for non-malignant CIF | 0 |
R20 | Change transparent dressing at most weekly | 0 |
R21 | Dressing omission on healed tunnelled catheter | 0 |
R22 | Administration tubing changed within 24 hours | 0 |
R23 | Aseptic technique for home catheter care | 0 |
R24 | Hand antisepsis and non-touch dressing change | 0 |
R25 | Use alcoholic chlorhexidine for skin antisepsis | 0 |
R26 | Clean hands before and after catheter access | 0 |
R27 | Needle-free connector for intravenous access | 0 |
R28 | Preference for split septum valves over mechanical valves | 0 |
R29 | Hub scrubbing and sterile access devices | 0 |
R3 | Consider HPN for CIF caused by cancer | 0 |
R30 | Antiseptic barrier caps for passive hub disinfection | 0 |
R31 | Weekly port needle replacement | 0 |
R32 | No unprotected immersion of catheter or site | 0 |
R33 | Saline instead of heparin for catheter lock | 0 |
R34 | Taurolidine lock to prevent bloodstream infection | 0 |
R35 | Sutureless securement for PICCs | 0 |
R36 | Anchored stabilisation device for longer-term PICCs | 0 |
R37 | Dedicated lumen for parenteral nutrition | 0 |
R38 | Avoid routine blood sampling from the catheter | 0 |
R39 | Ready-to-use admixtures or ones customised for the patient | 0 |
R4 | HPN when cancer life expectancy exceeds 1 to 3 months | 0 |
R40 | Compounding and aseptic preparation of admixtures | 0 |
R41 | Documented stability of each customised admixture | 0 |
R42 | No literature extrapolation of admixture stability | 0 |
R43 | Vitamins and trace elements added before infusion | 0 |
R44 | No drug addition without compatibility data | 0 |
R45 | Labelling admixtures for the individual patient | 0 |
R46 | Cold chain in transport and at home | 0 |
R47 | Maximum 24 hour hanging time | 0 |
R48 | Reduce the rate as a cyclic infusion ends | 0 |
R49 | Regular review of HPN treatment | 0 |
R5 | HPN without intestinal failure after informed discussion | 0 |
R50 | Individualised interval between HPN reviews | 0 |
R51 | Shared monitoring by hospital and home teams | 0 |
R52 | Training patients to self-monitor | 0 |
R53 | Scope of HPN monitoring | 0 |
R54 | Scheduled measurements during stable long-term HPN | 0 |
R55 | Annual vitamin and trace metal assessment | 0 |
R56 | Annual bone health assessment | 0 |
R57 | Home environment approval before HPN starts | 0 |
R58 | Training programme tailored to each patient | 0 |
R59 | Care provided by a dedicated HPN centre | 0 |
R6 | Train patient or caregiver to infuse HPN safely | 0 |
R60 | Outpatient rooms and dedicated beds | 0 |
R61 | Experienced nutrition support team for all patients | 0 |
R62 | Composition of the multidisciplinary nutrition support team | 0 |
R63 | Written pathways for HPN complications | 0 |
R64 | Written emergency information for patients | 0 |
R65 | Share protocols with emergency departments | 0 |
R66 | NST care on admission with a complication | 0 |
R67 | Share protocols with the patient's local hospital | 0 |
R68 | Travel documents and portal access | 0 |
R69 | Clarity on non-HPN professional roles | 0 |
R7 | Use an experienced provider for HPN delivery | 0 |
R70 | Safe travel with HPN supplies | 0 |
R71 | Quality criteria for the HPN programme | 0 |
R8 | Provide 24/7 NST monitoring and emergency contact | 0 |
R9 | NST and patient choose CVAD and exit site | 0 |
ST1 | Informed consent to HPN | 0 |
ST2 | Metabolic stability before discharge on HPN | 0 |
ST3 | Home environment suitable for HPN | 0 |
ST4 | Patient or carer able to perform procedures | 0 |
ST5 | Admixture matches what the patient needs | 0 |